MSH Capital Advisors LLC Sells 539 Shares of IQVIA Holdings Inc. $IQV

by · The Cerbat Gem

MSH Capital Advisors LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 22.7% during the second quarter, HoldingsChannel reports. The fund owned 1,832 shares of the medical research company’s stock after selling 539 shares during the quarter. MSH Capital Advisors LLC’s holdings in IQVIA were worth $289,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board raised its stake in IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after acquiring an additional 312,807 shares during the period. JPMorgan Chase & Co. raised its stake in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares during the period. American Century Companies Inc. raised its stake in IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after acquiring an additional 304,258 shares during the period. Dimensional Fund Advisors LP raised its stake in IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock valued at $251,852,000 after acquiring an additional 40,699 shares during the period. Finally, Pacer Advisors Inc. raised its stake in IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after acquiring an additional 854,732 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 1.3%

Shares of NYSE IQV opened at $203.16 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $237.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $34.54 billion, a price-to-earnings ratio of 29.40, a PEG ratio of 2.20 and a beta of 1.32. The business has a 50-day moving average of $188.70 and a 200-day moving average of $168.15.

IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $195.00 to $235.00 in a research report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday. Redburn Partners set a $214.00 price target on IQVIA in a research report on Wednesday, September 3rd. Robert W. Baird upped their price target on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Finally, Barclays upped their price target on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. Nineteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $236.45.

Get Our Latest Research Report on IQV

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).